Treatment patterns and outcomes for patients with advanced melanoma in US oncology clinical practices. (25th September 2018)

• Record Type: Journal Article
• Authors: Whitman, Eric D; Liu, Frank Xiaoqing; Cao, Xiting; Diede, Scott J; Haiderali, Amin; Abernethy, Amy P
• Is Part Of: Future oncology. Volume 15:Number 5(2019)
• Page Start: 459
• Page End: 471
• Publication Date: 2018-09-25
• Subjects: advanced melanoma -- antineoplastic therapy -- community oncology practice -- immuno-oncology -- observational study -- overall survival -- treatment pattern; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2018-0620
• Languages: English
• ISSNs: 1479-6694

Abstract

Aim: To describe recent evolution in treatment patterns and outcomes for advanced melanoma (AMel).Methods: This retrospective observational study analyzed de-identified electronic health record data from the Flatiron Health database for 1140 adult patients who initiated first-line therapy for AMel from 1 January 2014 to 30 June 2016 with follow-up through 28 February 2017.Results: The most common first-line regimens were ipilimumab-based therapies (34%), anti-PD-1 monotherapy (26%) and BRAF/MEK inhibitor(s) (20%). First-line ipilimumab-based and BRAF inhibitor regimens decreased after the third quarter of 2014 (3Q2014), and by 2Q2016, 55 and 91% of BRAF -mutant and BRAF wild-type cohorts, respectively, received a first-line anti-PD-1 regimen. Median overall survival from first-line initiation for all patients was 18.8 months (95% CI: 16.3–23.3).Conclusion: Results illustrate changing paradigms of therapy and real-world patient outcomes for AMel.